Semax: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข4 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store lyophilized Semax at -20 degrees Celsius protected from light. The reconstituted Russian pharmaceutical product should be stored at 2-8 degrees Celsius and used within the period specified on the packaging (typically 30 days). Research-grade reconstituted solutions should be refrigerated at 2-8 degrees Celsius and used within 2-4 weeks. Protect from light and oxidizing conditions. The methionine residue is susceptible to oxidation, so minimize exposure to air and UV light.
Protocol Quick-Reference
Cognitive enhancement, neuroprotection, and ischemic stroke treatment (approved in Russia)
Dosing
Amount
200-600 mcg per dose (0.1% solution) for nootropic use; 3-6 mg per dose (1% solution) for stroke
Frequency
2-3 times daily
Duration
10-14 day courses, repeated after 2-4 week break; 2-4 courses per year
Administration
Route
IntranasalSchedule
2-3 times daily
Timing
Morning and early afternoon; avoid late evening administration as it may interfere with sleep
Cycle
Duration
10-14 day courses, repeated after 2-4 week break; 2-4 courses per year
Rest Period
4 weeks off between cycles
Repeatable
Yes
Course-based protocol with rest periods
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Store lyophilized Semax at -20 degrees Celsius protected from light. The reconstituted Russian pharmaceutical product should be stored at 2-8 degrees Celsius and used within the period specified on the packaging (typically 30 days). Research-grade reconstituted solutions should be refrigerated at 2-8 degrees Celsius and used within 2-4 weeks. Protect from light and oxidizing conditions. The methionine residue is susceptible to oxidation, so minimize exposure to air and UV light.
โ๏ธ Suggested Bloodwork (6 tests)
CBC
When: Baseline
Why: General health baseline
CMP
When: Baseline
Why: Liver and kidney function
Fasting glucose
When: Baseline
Why: ~7% of diabetic patients report blood glucose elevation with Semax
Thyroid panel
When: Baseline
Why: Semax is an ACTH fragment; rule out adrenal/thyroid dysfunction
Cortisol (AM)
When: Baseline
Why: ACTH-derived peptide may influence HPA axis
Fasting glucose
When: End of 10-14 day course
Why: Monitor for glucose elevation, especially in diabetics
๐ก Key Considerations
- โ1% solution for acute stroke (medical supervision required)
- โContraindication: Not approved by FDA/EMA; caution in diabetes due to potential glucose elevation; caution with hypertension; avoid in pregnancy
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Cognitive enhancement and nootropic use (Russian approved) | 200-600 mcg per administration (0.1% solution, 2-6 drops per nostril) | 2-3 times daily | 10-14 day treatment courses | Based on the approved 0.1% Semax nasal drops (1 mg/mL) in Russia. Each drop delivers approximately 30 mcg. Standard nootropic course is 200-600 mcg per dose, 2-3 times daily for 10-14 days. Courses may be repeated after a 2-4 week break. Used for cognitive fatigue, attention difficulties, and mild cognitive impairment in Russian clinical practice. |
| Ischemic stroke (acute phase, Russian approved) | 3000-6000 mcg (3-6 mg) per administration | 2-4 times daily | 5-14 days | Uses the 1% Semax solution (10 mg/mL). Administered intranasally in the acute period of ischemic stroke. Initiated within hours of symptom onset. Higher doses used for moderate-severity strokes. This is an approved indication in Russia and is administered under medical supervision. |
| Optic nerve disease (Russian approved) | 200-600 mcg per administration (0.1% solution) | 2-3 times daily | 10-14 day treatment courses | Used in Russian clinical practice for optic nerve atrophy, glaucomatous optic neuropathy, and other optic nerve disorders. Typically administered as part of a broader neuroprotective treatment protocol. |
| Research protocol (subcutaneous) | 50-250 mcg/kg body weight | Once daily | Per study protocol | Weight-based dosing used in research settings. Dolotov et al. (2006) used 50 and 250 mcg/kg in rat studies demonstrating BDNF upregulation. Human dosing for research has not been standardized outside Russian clinical protocols. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
The Russian pharmaceutical product Semax is supplied as a ready-to-use 0.1% or 1% intranasal solution in dropper bottles and does not require reconstitution. For research-grade lyophilized Semax, reconstitute with sterile bacteriostatic water. For a 5 mg vial, add 2.5 mL bacteriostatic water for a concentration of 2 mg/mL. For intranasal research use, dilute to 0.1% (1 mg/mL) or 1% (10 mg/mL) in sterile normal saline with appropriate preservative. Gently swirl to dissolve; do not shake vigorously.
Recommended Injection Sites
- โIntranasal (primary route, both nostrils)
- โSubcutaneous (research route)
๐งStorage Requirements
Store lyophilized Semax at -20 degrees Celsius protected from light. The reconstituted Russian pharmaceutical product should be stored at 2-8 degrees Celsius and used within the period specified on the packaging (typically 30 days). Research-grade reconstituted solutions should be refrigerated at 2-8 degrees Celsius and used within 2-4 weeks. Protect from light and oxidizing conditions. The methionine residue is susceptible to oxidation, so minimize exposure to air and UV light.
Community Dosing Protocols
Compare these clinical doses with what 130+ community members report using.
Based on 130+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Administration Overview#
Semax is primarily administered via the intranasal route, which is the method used in all approved Russian pharmaceutical products and the vast majority of clinical research. The nasal mucosa provides a direct pathway to the central nervous system, bypassing the blood-brain barrier and hepatic first-pass metabolism. Subcutaneous injection is an alternative research route but is less commonly used.
Why Intranasal Administration?#
The intranasal route is preferred for Semax for several pharmacological reasons:
-
Direct CNS access: The olfactory epithelium in the upper nasal cavity provides a direct anatomical pathway to the brain via olfactory nerve axons. The trigeminal nerve branches in the nasal mucosa offer an additional pathway to the brainstem.
-
Bypasses the blood-brain barrier: Most peptides have poor blood-brain barrier penetration when administered systemically. Intranasal delivery circumvents this limitation.
-
Avoids first-pass metabolism: Oral administration of peptides results in rapid degradation by gastrointestinal proteases and hepatic enzymes. Intranasal delivery avoids this entirely.
-
Favorable molecular weight: At 814 Da, Semax is below the approximately 1000 Da molecular weight threshold that generally permits efficient transmucosal nasal absorption.
-
Non-invasive: Unlike subcutaneous injection, intranasal drops are painless and can be self-administered without special training.
Russian Approved Dosing Protocols#
Semax is approved in Russia in two formulations, each with distinct indications and dosing.
0.1% Semax Nasal Drops (1 mg/mL)#
The standard nootropic formulation delivers approximately 30 mcg per drop. The approved indications and dosing are:
Cognitive enhancement and mental fatigue:
- Dose: 200-600 mcg (approximately 2-6 drops per nostril)
- Frequency: 2-3 times daily
- Duration: 10-14 day treatment courses
- May be repeated after a 2-4 week interval
Cognitive dysfunction in children and adolescents (ages 7-18):
- Dose: 200-400 mcg (2-4 drops per nostril)
- Frequency: 2 times daily
- Duration: 10-14 days
Optic nerve disease:
- Dose: 200-600 mcg per administration
- Frequency: 2-3 times daily
- Duration: 10-14 days
- Used as part of comprehensive neuroprotective treatment
1% Semax Nasal Drops (10 mg/mL)#
The high-concentration formulation is reserved for serious neurological conditions:
Acute ischemic stroke (moderate severity):
- Dose: 3000-6000 mcg (3-6 mg) per administration
- Frequency: 2-4 times daily
- Duration: 5-14 days depending on clinical response
- Must be initiated under medical supervision during the acute period
Dyscirculatory encephalopathy:
- Dose: 3000 mcg per administration
- Frequency: 2-3 times daily
- Duration: 14 days
- May be combined with standard cerebrovascular therapy
Intranasal Administration Technique#
Proper intranasal administration is important for optimal drug delivery:
-
Preparation: Clear nasal passages before administration. If nasal congestion is present, consider using a gentle saline rinse first, as congestion reduces absorption.
-
Positioning: Tilt the head slightly forward (not backward). This positions the drops toward the olfactory epithelium in the upper nasal cavity, which is the primary absorption site for CNS delivery.
-
Administration: Using the dropper bottle, instill the prescribed number of drops into each nostril. Alternate nostrils if the total dose requires multiple drops.
-
Post-administration: Remain in the tilted-forward position for 15-30 seconds. Avoid blowing the nose for at least 10-15 minutes after administration.
-
Timing: Semax is typically administered in the morning or early afternoon. Due to its cognitive-activating properties, late evening administration may interfere with sleep in some individuals.
Research Dosing Considerations#
Weight-Based Dosing in Preclinical Studies#
In animal research, Semax is typically dosed on a body weight basis:
| Study | Species | Dose | Route | Key Finding |
|---|---|---|---|---|
| Dolotov et al. (2006) | Rat | 50 mcg/kg | Intranasal | BDNF increase in basal forebrain |
| Dolotov et al. (2006) | Rat | 250 mcg/kg | Intranasal | Higher BDNF increase, same region |
| Eremin et al. (2005) | Mouse | 150 mcg/kg | Intraperitoneal | Serotonin metabolite increase to 180% |
| Medvedeva et al. (2014) | Rat | 100 mcg/kg | Intranasal | Gene expression changes post-stroke |
Allometric Considerations#
Direct translation of animal doses to human doses using simple body weight scaling is inappropriate for intranasal peptides. The relevant pharmacological considerations include differences in nasal cavity surface area, olfactory epithelium proportion, enzymatic activity, and CSF volume between species. The Russian approved doses for humans (200-6000 mcg total dose, not weight-based) were established through clinical development, not allometric scaling from animal studies.
NA-Semax (N-Acetyl Semax)#
NA-Semax is a modified derivative with an acetyl group on the N-terminal methionine. This modification is reported to extend the biological half-life to 6-12 hours compared to 2-4 hours for standard Semax. NA-Semax is not part of the approved Russian pharmaceutical product and exists only as a research chemical. No standardized dosing protocols exist for NA-Semax, and users should be aware that pharmacological equivalence to standard Semax has not been established.
Treatment Course Structure#
In Russian clinical practice, Semax is typically administered in structured treatment courses rather than continuously:
- Standard course: 10-14 days of daily administration
- Rest period: 2-4 weeks without Semax
- Repeat course: If clinically indicated
- Total courses: 2-4 courses per year for chronic conditions
This cyclical approach is standard in Russian neuropeptide therapeutics and is believed to prevent receptor desensitization, though the evidence for this rationale is limited.
Important Dosing Considerations#
- Semax is not approved by the FDA, EMA, or other Western regulatory agencies
- All dosing protocols described here are based on Russian pharmaceutical approvals and preclinical research
- The acute stroke dosing protocol requires medical supervision and should only be administered in clinical settings
- Individuals with diabetes should monitor blood glucose, as an increase in blood glucose levels has been reported in approximately 7% of diabetic patients in Russian clinical observation
- There is no established maximum safe dose from Western-standard clinical trials
- Drug interactions have not been systematically studied in controlled trials
Evidence Gaps#
- No Western-standard dose-finding studies have been conducted
- Comparative bioavailability between intranasal and subcutaneous routes not formally characterized in humans
- Optimal dosing for specific cognitive domains (memory, attention, executive function) not differentiated
- Dose-response relationships for BDNF modulation in humans not established
- Safety and efficacy of long-term continuous (vs. cyclical) administration not compared
- NA-Semax and NA-Semax-Amidate dosing is entirely anecdotal
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Semax
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.